For investors
A large, growing and unaddressed market; a validated platform for high throughput screening of candidate drugs; and a plan designed to build defensible value early in development.
Keratinocyte skin cancers - squamous cell and basal cell carcinoma - are the most common malignancies in humans. For people at high risk they are relentless: transplant recipients, people on immunosuppression, those with genetic conditions such as Gorlin syndrome, and the heavily sun-damaged develop tumour after tumour, each one needing surgery.
It is painful, disfiguring and costly, and today there is no approved medicine that can protect these patients from developing new cancers.
In the major markets about 1.8 million people keep developing new basal or squamous cell carcinomas: about 33,000 with Gorlin syndrome, 1.0-1.5 million with multiple sporadic BCC, around one in five of the 0.8-1.0 million living transplant recipients - who carry a 65-100x increased risk of squamous cell carcinoma - and 400,000-600,000 with multiple sporadic squamous cell carcinoma. Almost all are already under regular dermatology review.
Payers already fund drug treatment for the highest-burden patients: NHS England pays for vismodegib in Gorlin syndrome and for people with six or more BCCs. With a price benchmarked on vismodegib, our base case is peak sales of about £400m a year in Gorlin syndrome alone, and about £8.8bn a year if a single drug could prevent both basal and squamous cell carcinoma.
At the heart of Epistat is a proprietary 3D human-tissue platform that models how skin cancers actually begin, at the earliest steps of the disease. It is disease-validated - a known medicine blocks the disease process in the model - and it is built for high-throughput screening.
That means it can generate many preventive drug candidates across different biology, rather than betting the company on a single molecule.
We are building a pipeline on two tracks: repurposed medicines, whose existing safety record offers a fast, de-risked route to patients, and novel compounds designed for stronger, longer-lasting protection. Candidates are being developed for both topical and systemic use.
Epistat is led by Dr Magnus Lynch, a consultant dermatologist and Mohs surgeon who is an expert in the treatment of complex keratinocyte-derived skin cancers as well as an Honorary Reader and Principal Investigator at King's College London. He has published 50 peer-reviewed papers and is senior author on the first single-cell and spatial map of basal cell carcinoma, produced as part of the Human Cell Atlas.
That combination is difficult to replicate: fresh tumour samples move from Dr Lynch's operating list to the laboratory the same day, and the company has direct access to the very-high-risk patient groups - transplant recipients, the immunosuppressed, Gorlin syndrome - in whom a preventive treatment can be tested.
The science is validated, no existing treatment prevents both cancers in a form patients can stay on, and growing interest in prevention among dermatologists signals an enormous market opportunity.
Our near-term priorities are to secure a broad intellectual property portfolio and establish partnerships with pharmaceutical companies. We are raising a seed round to build a broad, protected portfolio of preventive candidates on the platform, ahead of animal studies and a first-in-human prevention trial.
A detailed plan, data and the current round will be shared with potential investors on request.
A founding team that combines expertise in the diagnosis and treatment of complex keratinocyte carcinomas, laboratory science and the assay at the core of the platform, supported by King's College London and the King's Spinout Accelerator.
We are actively building our advisory board and would welcome introductions to clinical, scientific and biotech operators who can help guide the company.
Get in touch
Request our investor materials and we will be in touch. We share the deck, data and current round under confidence.